Development of echinocandin-resistant Candida albicans candidemia following brief prophylactic exposure to micafungin therapy

Transplant Infectious Disease

Volumn 16, Issue 3, 2014, Pages 469-472

  Ruggero, M A ^a   Topal, J E ^a,b  

^a YALE NEW HAVEN HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breakthrough; C. albicans; Echinocandin; Fks1; Resistance; Stem cell transplant

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMPHOTERICIN B; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CASPOFUNGIN; CIPROFLOXACIN; ECHINOCANDIN; METHYLPREDNISOLONE; MICAFUNGIN; MYCOPHENOLIC ACID; TACROLIMUS; VORICONAZOLE; ANTIFUNGAL AGENT; LIPOPEPTIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CULTURE; BROTH DILUTION; CANDIDA ALBICANS; CANDIDEMIA; CASE REPORT; CONSOLIDATION CHEMOTHERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FUNGUS GROWTH; FUNGUS ISOLATION; GRAFT VERSUS HOST REACTION; HUMAN; LIVER FUNCTION TEST; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SYSTEMIC MYCOSIS; TREATMENT DURATION; ALLOTRANSPLANTATION; ANTIFUNGAL RESISTANCE; DRUG EFFECTS; FATALITY; LEUKEMIA, MYELOID, ACUTE; MICROBIOLOGY; STEM CELL TRANSPLANTATION;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDEMIA; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FATAL OUTCOME; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIPOPEPTIDES; MIDDLE AGED; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; VORICONAZOLE;

EID: 84901931370     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12230     Document Type: Article

References (21)

1. Pizzo PA, Robichaud KJ, Gill FA, et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72 (1): 101-111.
2. Gerson SL, Talbot GH, Hurwitz S, et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984; 100 (3): 345-351.
3. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52 (4): e56-e93.
4. NCCN.org. NCCN Clinical Practice Guidelines in Oncology: Prevention and treatment of cancer-related infections. Version 2.2011. Fort Washington, PA: National Comprehensive Cancer Network, June 2011.
5. Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL the 3-2009 update. Bone Marrow Transplant 2011; 46: 709-718.
6. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407-1416.
7. Castanheira M, Woolsey LN, Diekema DJ, et al. Low prevalence of fks1 hot spot 1 Candida strains mutations in a worldwide collection of Candida strains. Antimicrob Agents Chemother 2010; 54 (6): 2655-2659.
8. Garcia-Effron GS, Katiyar K, Park S, et al. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 2008; 52: 2305-2312.
9. Garcia-Effron G, Park S, Perlin DS. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for C. albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 2009; 53 (1): 112-121.
10. Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive as species specific interpretive criteria. Drug Resist Updat 2011; 14: 164-176.
11. Park S, Kelly R, Kahn JN, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005; 49: 3264-3273.
12. Douglas CM. Fungal beta(1, 3)-D-glucan syntheses. Med Mycology 2001; 39 (Suppl 1): 55-66.
13. Cleary JD, Garcia-Effron G, Chapman SW, et al. Reduced Candida glabrata susceptibility secondary to FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother 2008; 52 (6): 2263-2264.
14. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007; 10: 121-130.
15. Lewis JS, Wiederhold NP, Wickes BL, et al. Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. Antimicrob Agents Chemother 2013; 57 (9): 4559-4561.
16. Pfeiffer CD, Garcia-Effron G, Zaas AK, et al. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 2010; 48 (7): 2373-2380.
17. Glockner A. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin - review of the literature. Eur J Med Res 2011; 16: 167-179.
18. Pfaller MA, Messer SA, Woolsey RN, et al. Echinocandin and triazole antifungal susceptibility profiles of clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol 2013; 51 (8): 2571-2581.
19. Slater JL, Howard SJ, Sharp A, et al. Disseminated candidiasis caused by Candida albicans with amino acid substitution in Fks1 at position Ser645 cannot be successfully treated with micafungin. Antimicrob Agents Chemother 2011; 55 (7): 3075-3083.
20. Ben-Ami R, Garcia-Effron G, Lewis RE, et al. Fitness and virulence costs of FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis 2011; 204: 626-635.
21. Ben-Ami R, Kontoyiannis DP. Resistance to echinocandins comes at a cost. Virulence 2012; 3 (1): 95-97.